TRIAL DETAIL

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Drug:
Trial Name:
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 02/01/2008
Age of Trial (yrs) 16.2
Treatment Phase:
Gleevec-resistant
Drug Category:
HSP90 inhibitor
Strategy:
Destroy KIT
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
120ST103
Sponsor:
Biogen Idec
Patient Contact:
Biogen Idec oncologyclinicaltrials@biogenidec.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
BIIB021 is an oral third-generation Hsp90 inhibitor and is manufactured by Biogen Idec.

Trial Links

 
 
 

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
2020 Santa Monica Boulevard Suite 600
Santa Monica
CA
90404
USA
4319 Medical Dr.
San Antonio
TX
78229
USA
477 N. El Camino Real
Encinitas
CA
92024
USA